| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Cocrystal Pharma, Inc.
13D/A
Amendment 1
COCP · 19188J409
|
29.6% |
11/6/2026
Event 11/4/2026
|
|||
| Opko Health, Inc. | 29.6% | ||||
| Frost Phillip MD Et Al | 13.9% | ||||
| Frost Gamma Investments Trust | 13.6% | ||||
| Rubin Steven D | 0.4% | ||||
|
Cocrystal Pharma, Inc.
13D
COCP · 19188J409
|
29.6% |
8/7/2026
Event 7/31/2026
|
|||
| Opko Health, Inc. | 29.6% | ||||
| Frost Phillip MD Et Al | 13.9% | ||||
| Frost Gamma Investments Trust | 13.6% | ||||
| Rubin Steven D | 14.1% | ||||
|
Entera Bio Ltd.
13G
ENTX · M40527109
|
8.1% |
4/2/2025
Event 3/16/2025
|
|||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.